IL-1ra as a Therapeutic Modality in Sepsis

  • S. M. Opal
Conference paper
Part of the Yearbook of Intensive Care and Emergency Medicine 1993 book series (YEARBOOK, volume 1993)


It has become increasingly evident that our current therapeutic options in the treatment of sepsis are limited and result in an unacceptable high mortality rate. The outcome in severe sepsis and septic shock has not changed appreciably despite improvements in critical care medicine and the introduction of a number of potent, broad-spectrum antimicrobial agents over the past two decades. Septic shock has become a leading cause of mortality in critical care units and current trends would indicate that sepsis will become increasingly common in the future. Clearly, innovative treatment strategies are needed to support the septic patient and improve the outlook in this potentially devastating clinical Syndrome [1].


Septic Shock Septic Patient Endotoxin Challenge Soluble Cytokine Receptor Total Hospital Length 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Bone RC (1991) Pathogenesis of Sepsis. Ann Intern Med 115: 457–469PubMedGoogle Scholar
  2. 2.
    Dinarello CA (1991) The proinflammatory cytokines interleukin-1 and tumor necrosis factor in the treatment of septic shock Syndrome. J Inf Dis 136: 1177–1184CrossRefGoogle Scholar
  3. 3.
    Seckinger P, Lowenthal JW, Williamson K, Dayer J, McDonald HR (1987) A urine inhibitor of interleukin-1 activity that blocks ligand binding. J Immunol 139: 1546–1549PubMedGoogle Scholar
  4. 4.
    Dinarello CA (1988) Biology of interleukin-1. FASEB J 2: 108–115PubMedGoogle Scholar
  5. 5.
    Oppenheim JJ, Matsushima K, Yoshimura T, Leonard EJ, Nata R (1989) Relationship between interleukin-1 (IL-1), tumor necrosis factor (TNF) and a neutrophil attracting peptide (NAP-1). Agents Actions 26: 134–140PubMedCrossRefGoogle Scholar
  6. 6.
    Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA (1988) Interleukin-1 induces a shock-like State in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxyge- nase inhibition. J Clin Invest 81: 1162–1172Google Scholar
  7. 7.
    Arend WP, Joslin FG, Thompson RC, Hannum CH (1989) An IL-1 inhibitor from human mo- nocytes. Production and characterization of biologic properties. J Immunol 143: 1851–1858Google Scholar
  8. 8.
    Seckinger P, Dayer JM (1987) Interleukin-1 inhibitors. Ann Inst Pasteur/Immunol 138: 461–516CrossRefGoogle Scholar
  9. 9.
    Eisenberg SP, Evans RJ, Arend WP, et al. (1990) Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 343: 141–146CrossRefGoogle Scholar
  10. 10.
    Dinarello CA, Thompson RC (1991) Bloeking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12: 404–410PubMedCrossRefGoogle Scholar
  11. 11.
    Ohlsson K, Bjork P, Bergenfeldt M, Hageman R, Thompson RC (1990) Interleukin-1 receptor antagonist reduces modality from endotoxin shock. Nature 348: 550–552PubMedCrossRefGoogle Scholar
  12. 12.
    Fischer E, Marino MA, VanZee KJ, et al. (1992) Interleukin-1 receptor blockade improves survival and hemodynamic Performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia. J Clin Invest 89: 1551–1557PubMedCrossRefGoogle Scholar
  13. 13.
    Aiura K, Gelfand JA, Wakabayashi G, et al. (1991) Interleukin-1 receptor antagonist blocks hypotension in a rabbit mpdel of gram-positive septic shock. Cytokine 3: 498Google Scholar
  14. 14.
    Granowitz EV, Porat R, Mier JW, et al. (1992) Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans. Cytokine 4: 353–360PubMedCrossRefGoogle Scholar
  15. 15.
    Granowitz EV, Santos AA, Poutsiaka DD, et al. (1991) Production of interleukin-1 receptor antagonist during experimental endotoxaemia. Lancet 33A: 1423–1424CrossRefGoogle Scholar
  16. 16.
    Fisher CJ, Slotman G, Opal S, Pribble J, Catalano M, and the IL-lra Sepsis Study Group (1991) Results of a phase II study of IL-lra in the treatment of sepsis Syndrome. American College of Chest Physicians 57th Annual Meeting San Francisco CaliforniaGoogle Scholar
  17. 17.
    Opal SM, Fischer CJ, Slotman GJ, et al., and the IL-lra Sepsis Study Group (1992) Phase II interleukin-1 receptor antagonist sepsis Syndrome trial: Analysis of clinical, cytokine, and microbial features with outcome. 32nd Annual Meeting of the Interscience Conference of Antimicrobial Agents and Chemotherapy, Anaheim California Abst 1570Google Scholar
  18. 18.
    Gordon G, Fisher CJ, Opal SM, Pribble J, Catalano M (1992) Cost-effectiveness of interleukin-1 receptor antagonist in sepsis. Clin Res 40 (Abst) 254 AGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1993

Authors and Affiliations

  • S. M. Opal

There are no affiliations available

Personalised recommendations